CORRELATIONS BETWEEN SERUM LEVEL OF MATRIX METALLOPROTEINASE-9 (MMP-9) AND SERUM LEVEL OF TROPONIN-I IN PATIENT WITH ACUTE CORONARY SYNDROME (ACS)

Ruchanihadi Ruchanihadi; Budi Yuli Setianto; Hariadi Hariawan

doi:10.22146/acta interna.3865

CORRELATIONS BETWEEN SERUM LEVEL OF MATRIX METALLOPROTEINASE-9 (MMP-9) AND SERUM LEVEL OF TROPONIN-I IN PATIENT WITH ACUTE CORONARY SYNDROME (ACS)

https://doi.org/10.22146/acta%20interna.3865

Ruchanihadi Ruchanihadi^(1*), Budi Yuli Setianto⁽²⁾, Hariadi Hariawan⁽³⁾

(1)
(2)
(3)
(*) Corresponding Author

Abstract

ABSTRACT

Background. The pathophysiology of acute coronary syndromes (ACS) is now accepted as the rupture or erosion of an atherosclerotic plaque, initially occurs at the shoulder of the plaque and is followed by intra-plaque thrombosis then spread to the vascular lumen and cause total partial vascular occlusion. MMP-9 is an extracellular matrix degrading enzyme that plays a crucial role in the breakdown of the fibrous cap of plaque and subsequent rupture in the pathogenesis of ACS. Cardiac troponins are currently the most sensitive and specific biochemical markers of myocytes necrosis.

Objective. To know the correlation between serum level MMP-9 and serum level of Troponin-I in patients with ACS

Method. Study design was cross sectional. Data were collected by consecutive sampling from patients in ICCU board of RSUP Dr. Sardjito Yogyakarta, in June 2008-August 2010. A questionnaire was used to collect information from patient. After admission, peripheral venous blood was drawn once and measuring concentration of serum level of MMP-9 and Troponin-I before definitive thrombolysis. Data are expressed as means ± standard deviation (SD). Correlation between serum level of MMP-9 and serum level of Troponin-I were assessed using Spearman’s rank correlations test. A value of p<0.05 was considered statistically significant.

Result. There were 139 patients with ACS and comprising 63 patients with STEMI, 27 patients with NSTEMI, and 49 patients with UAP. Means±SD of Troponin-I from all of samples was 9.49±10.47 ng/dL. Mean±SD of MMP-9 from all of samples was 1296.06±729.97 ng/dL. There were significant correlations between MMP-9 and Troponin-I in patients with ACS (r=0.34, p=0.000).

Conclusion. There were significant correlations between MMP-9 and Troponin-I in ACS patients in ICCU RSUP Dr. Sardjito Yogyakarta.

Keywords: ACS, MMP-9, Troponin-I

Full Text:

PDF

References

Collinson, P.O., Gaze, D.C. Biomarkers of Cardiovascular Damage and Dysfunction-An Overview, Heart, Lung and Circulation; 2007:16:S71–S82.

Rackley2, C.E. Pathogenesis of plaque ruptur in acute coronary syndromes, Up to Date, 2008. Ver 16.3

Tan, J., HATS, Q., Gao, J., Fan, Z.X. Clinical Implications of Elevated Serum Interleukin-6, Soluble CD40 Ligand, Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 in Patients with Acute ST-segment Elevation Myocardial Infarction, Clin. Cardiol; 2008: 31: 9: 413–418.

Apple, F.S., Wu, A.H.B., Mair, J., Ravkilde., Panteghini, M., Tate, J., Pagani, F., et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome, Clinical Chemistry; 2005; 51, No. 5, 810–824.

Higo, S., Uematsu, M., Yamagishi, M., Ueda, H.I., Awata, M., Morozumi,T., Ohara, T., Nanto, S., Nagata, S. Elevation of Plasma Matrik Metalloproteinase-9 in the Culprit Coronary Artery in Patients With Acute Myocardial Infarction Clinical Evidence From Distal Protection, Circulation Journal, 2005: Vol.69, October:1180-1185.

Kaden, J.J., Dempfle, C.E., Sueselbeck, T., Brueckmann, M., Poerner, T.C., Haghi, D., Haase, K.K., Borggrefe, M. Time-Dependent Changes in the Plasma Concentration of Matrik Metalloproteinase 9 after Acute Myocardial Infarction, Cardiology; 2003 : 99:140–144.

Jaffe, A.S. Troponins, creatine kinase, and CK isoforms as biomarkers of cardiac injury, UpToDate 2007 ver 16.3.

Alexander, R.W., Ryan, T.J., Pratt, C.M., Roberts, R. Diagnosis and Management of Patients With ST-Segment-Elevation Myocardial infaction, in: O’rouke, RA., Fuster, V., Alexander, R.W., Roberts, R., King, S.B., Prystowsky, E.N., Nash, I.S., editor., Hurst’s The Heart, Manual of Cardiology, 11ed, 2005. :251-286. The McGraw-Hill Companies, Singapore.

Reeder, G.S., Kennedy, H.L., Diagnosis of an acute myocardial infarction, Up ToDate 2008 ver 16.3.

Hochholzer, W., Buettner, H.J., Trenk, D., Laule, K., Christ, M., Neumann, F.J., Mueller, C. New Definition of Myocardial Infarction: Impact on Long-term Mortality The American Journal of Medicine; 2008:121: 399-405.

Roongsritong, C., Warraich, I., Bradley C. Common Causes of Troponin Elevations in the Absence of Acute Myocardial Infarction, Incidence and Clinical Significance, Chest 2004;125;1877-1884.

Dahlan1, M.S., Statistik untuk kedokteran dan kesehatan, edisi 3, 2005. Arkan, Jakarta.

Alwi, I. Tatalaksana Infark miokard Akut dengan Peningkatan ST, dalam: Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibrata, K.M., Setiati, S. editor. Buku Ajar Ilmu Penyakit Dalam, Jilid III, edisi IV, 2006: 1630-1640. Pusat Penerbitan Departemen Ilmu Penyakit Dalam FK-UI, Jakarta.

Milner, J.M., dan Cawston, T.E. Matrik Metalloproteinase Knockout Studies and the Potential Use of Matrik Metalloproteinase Inhibitors in the Rheumatic Diseases, Current Drug Targets - Inflammation & Allergy; 2005: 4: 363-375.

Creemers, E.E.J.M., Cleutjens, J.P.M., Smits, J.F.M., Daemen, M.J.A.P., 2001. Matrik Metalloproteinase Inhibition After Myocardial Infarction A New Approach to Prevent Heart Failure?, Circ Res. 2001;89:201-210.

Galis, Z.G., Khatri, J.J. Matrik Metalloproteinases in Vascular Remodeling and Atherogenesis, The Good, the Bad, and the Ugly, Circ Res; 2002:90:251-262.

Newby, A.C. Dual Role of Matrik Metalloproteinases (Matrikins) in Intimal Thickening and Atherosclerotic Plaque Ruptur, Physiol Rev, 2005: Vol 85:1-31.

Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seki, Y., Kuwahara, F., et al. Peripheral blood levels of matrik metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol; 1998: 32:368–72.

Fukuda, D., Shimada, K., Tanaka, A., Kusuyama, T., Yamashita, H., Ehara, S., Nakamura, Y., Kawarabayashi, T., Iida, H., Yoshiyama, M., Yoshikawa, J. Comparison of Levels of Serum Matrik Metalloproteinase-9 in Patients With Acute Myocardial Infarction Versus Unstable Angina Pectoris Versus Stable Angina Pectoris, Am J Cardiol; 2006:97:175–180.

Dahlan2, M.S.,. Besar sampel dalam penelitian kedokteran dan kesehatan, 2005: hal: 5-18, Arkan, Jakarta

Manginas, A., Bei, E., Chaidaroglou, A., Degiannis, D., Koniavitou, K., Voudris, V., Pavlides, G., Panagiotakos, D., Cokkinos, D.V. Peripheral Levels of Matrik Metalloproteinase-9, Interleukin-6, and C-Reactive Protein Are Elevated in Patients with Acute Coronary Syndromes: Correlations with Serum Troponin I., Clin. Cardiol. 2005:28, 182–186.

Tan, J., HATS, Q., Gao, J., Fan, Z.X.. Clinical Implications of Elevated Serum Interleukin-6, Soluble CD40 Ligand, Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 in Patients with Acute ST-segment Elevation Myocardial Infarction, Clin. Cardiol; 2008: 31: 9: 413–418.

Eckart, R.E.D.O., Uyehara, C.F.T., Shry, E.A., Furgerson, J.L., Krasuski, R.A. Matrix metalloproteinases in patient with myocardial infarction and percutaneous revascularization, J Interven Cardiol; 2004: 17:27-31.

DOI: https://doi.org/10.22146/acta%20interna.3865